How much funding has Tango Therapeutics raised?

Tango Therapeutics has raised $235.0M in total funding, most recently a Series C round.

Who are Tango Therapeutics's investors?

Tango Therapeutics's investors include Boxer Capital, BCTG Acquisition Corp., Third Rock Ventures, Farallon Capital, Balyasny Asset Management, T. Rowe Price.

When was Tango Therapeutics founded?

Tango Therapeutics was founded in 2017.

Where is Tango Therapeutics headquartered?

Tango Therapeutics is headquartered in Cambridge, Massachusetts, United States.

What industry is Tango Therapeutics in?

Tango Therapeutics operates in Biotech, Healthcare.

How many employees does Tango Therapeutics have?

Tango Therapeutics has 51-200 employees.

Tango Therapeutics

IPO

Discovering the next generation of precision cancer medicines

Public · Cambridge, United States · Founded 2017 · $235.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2017
Business Model: B2B
Website: tangotx.com

Total Funding: $235.0M
Last Round: $120.0M Series CMay 2025
Rounds: 3
Type: Public

About

Tango Therapeutics is a clinical-stage biotechnology company leveraging the principle of synthetic lethality to discover novel drug targets and develop precision cancer medicines. The company's integrated discovery platform uncovers vulnerabilities arising from tumor suppressor gene loss in specific cancer types, enabling targeted therapies for genetically defined patient populations with limited treatment options.

Summary

Tango Therapeutics is a Biotech company based in Cambridge, United States, founded in 2017. It has raised $235.0M in total across 3 rounds, most recently a $120.0M Series C round in May 2025. Investors include Boxer Capital, BCTG Acquisition Corp. and Third Rock Ventures.